Skip to main content

Advertisement

Log in

Posaconazole

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Posaconazole (Noxafil; Schering–Plough), a triazole antifungal drug, was approved by the US FDA in September 2006 for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections owing to being severely immunocompromised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Posaconazole.

References

  1. Kauffman, C. A. Clinical efficacy of new antifungal agents. Curr. Opin. Microbiol. 9, 483–488 (2006).

    Article  CAS  Google Scholar 

  2. Torres, H. A. et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5, 775–785 (2005).

    Article  CAS  Google Scholar 

  3. Odds, F. C. et al. Antifungal agents: mechanisms of action. Trends Microbiol. 11, 272–279 (2003).

    Article  CAS  Google Scholar 

  4. Bennett, F. et al. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg. Med. Chem. Lett. 16, 86–90 (2006).

    Article  Google Scholar 

  5. Ullmann, A. J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335–347 (2007).

    Article  CAS  Google Scholar 

  6. Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348–359 (2007).

    Article  CAS  Google Scholar 

  7. FDA labelling information [online], < http://www.fda.gov/cder/foi/label/2006/022003lbl.pdf > (2006).

  8. Kauffman, C. A. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis. 39, 588–590 (2004).

    Article  Google Scholar 

  9. Greenberg, R. N. et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50, 126–133 (2006).

    Article  CAS  Google Scholar 

  10. Van Burik, J. H. et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42, e61–e65 (2006).

    Article  CAS  Google Scholar 

  11. Walsh, T. J. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44, 2–12 (2007).

    Article  CAS  Google Scholar 

  12. Raad, I. I. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42, 1398–1403 (2006).

    Article  CAS  Google Scholar 

  13. Anstead, G. M. et al. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis. 40, 1770–1776 (2005).

    Article  CAS  Google Scholar 

  14. Johnson, L. B. & Kauffman, C. A. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630–637 (2003).

    Article  CAS  Google Scholar 

  15. Sansone-Parsons, A. et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50, 1881–1883 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kauffman, C., Malani, A., Easley, C. et al. Posaconazole. Nat Rev Drug Discov 6, 183–184 (2007). https://doi.org/10.1038/nrd2270

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2270

  • Springer Nature Limited

This article is cited by

Navigation